Thermo Fisher Scientific Inc (TMO) PT Raised to $207.00 at Leerink Swann

Thermo Fisher Scientific Inc (NYSE:TMO) had its price target hoisted by Leerink Swann from $190.00 to $207.00 in a research note issued to investors on Monday. Leerink Swann currently has an outperform rating on the medical research company’s stock.

A number of other research firms also recently weighed in on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a hold rating to a buy rating and set a $212.00 price objective on the stock in a report on Thursday, September 21st. Bank of America Corporation reaffirmed a buy rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cowen and Company reaffirmed an outperform rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. BidaskClub downgraded Thermo Fisher Scientific from a strong-buy rating to a buy rating in a report on Monday, July 31st. Finally, Barclays PLC reissued an overweight rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific currently has an average rating of Buy and an average price target of $203.64.

Thermo Fisher Scientific (NYSE TMO) opened at 193.39 on Monday. The firm’s 50-day moving average price is $188.78 and its 200-day moving average price is $174.98. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $194.30. The company has a market cap of $75.45 billion, a P/E ratio of 33.69 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.03 earnings per share. Analysts expect that Thermo Fisher Scientific will post $9.35 EPS for the current year.

WARNING: “Thermo Fisher Scientific Inc (TMO) PT Raised to $207.00 at Leerink Swann” was first published by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/thermo-fisher-scientific-inc-tmo-pt-raised-to-207-00-at-leerink-swann/1704055.html.

In related news, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. Insiders sold a total of 52,738 shares of company stock valued at $9,302,112 in the last 90 days. 0.49% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of TMO. Proficio Capital Partners LLC raised its position in Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $108,000. Cribstone Capital Management LLC raised its position in Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the last quarter. Sharkey Howes & Javer raised its position in Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $113,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with our FREE daily email newsletter.

 


Latest News

Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley


Leave a Reply

 
© 2006-2017 BBNS.